Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

437P - Early gastric cancer detection with AI-enabled routine blood test: A territory-wide clinical big-data study

Date

27 Jun 2024

Session

Poster Display session

Presenters

Minji Seo

Citation

Annals of Oncology (2024) 35 (suppl_1): S162-S204. 10.1016/annonc/annonc1482

Authors

M. Seo1, K.M. Cheung2, S.J.L. Lam3, W. Sung2, P.Y.M. Woo3, J.C. Chow2, A.S.M. Yip4, S.K.K. Ng3, M. Lee2, D.M.Y. Kan4, S. Kao2, H.H.Y. Yiu2, D.C.C. Lam1

Author affiliations

  • 1 HKUST - The Hong Kong University of Science and Technology, Kowloon/HK
  • 2 Queen Elizabeth Hospital, Kowloon/HK
  • 3 The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin/HK
  • 4 Kwong Wah Hospital, Kowloon/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 437P

Background

A four-week delay in cancer treatment delay was shown to increase mortality. Gastric cancer survival can be improved if the cancer is detected early. A big-clinical-data AI model was developed using routine blood test data in > 275,000 dyspepsia patients within 30 days of diagnosis in the Hong Kong Hospital Authority Data Collaboration Laboratory. The model demonstrated that 80% of GC patients and 80% of dyspepsia patients could be detected accurately. This study assesses the early detection capabilities of this model using a new cohort.

Methods

This study included patients with prescribed medications for dyspepsia for over 2 months. GC patients were identified with ICD codes, and cases with other cancers were excluded. Blood records (complete blood count, liver/renal function test, and clotting profiles) were retrieved from three time intervals: 1-3, 3-6, and 6-12 months before diagnosis. A risk score with a range from 0 to 1 was calculated for each period and scores > 0.35 were categorized as GC positive. The lead time between correctly predicted positive and diagnosis date were calculated for each patient. The sensitivity and specificity at each time interval were calculated to determine the early detection capability.

Results

Overall, 1,456 GC and 25,531 dyspepsia patients had records from the specified periods. GC patients exhibited an increasing trend in the risk scores as the diagnosis date approached. The model found 365 out of 576 (64%), 203 out of 406 (50%), 205 out of 474 (43%) GC patients early, in the corresponding time intervals. The median lead time for GC detection was 7.1 months ahead of diagnosis. The median specificity over the three periods was 70%. The risk score for negative controls remained negative with high precision (SD 0.03).

Conclusions

The data showed that the AI-enabled routine blood test model could detect GC by 7.1 months earlier than GC diagnosis. Up to 40% of gastric cancer patients could have their GC diagnosed 1 year earlier. This creates a meaningful time window for curative intervention and therefore, indicates its potential in reducing cancer mortality.

Legal entity responsible for the study

Department of Mechanical and Aerospace engineering, HKUST.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.